The Closed-Loop Skincare System That's Leading the Industry
In an era where consumers demand both clinical efficacy and at-home convenience, Derminous has redefined the boundaries of skincare with its GeneLift™ Micro-Infusion System—a fully integrated, closed-loop anti-aging protocol that merges medical-grade science with ritualistic self-care. Unlike traditional microneedling or superficial serums, this system operates as a precision delivery ecosystem: from 24K gold-coated micro-channels that enhance absorption by up to 300%[1] , to patented actives like PDRN (Polydeoxyribonucleotide) and biomimetic peptides that stimulate collagen regeneration at the cellular level[2] .

What sets Derminous apart is its end-to-end design philosophy. Every component—from the single-use, sterile micro-infusion device to the post-treatment cryo-mask and barrier-repairing cream—is engineered to work in concert, ensuring maximum bioavailability, minimal irritation, and sustained results. Clinical-inspired yet DTC-optimized, it caters to the growing global demand for “medical aesthetics without the clinic”[3] . With no downtime, no pain, and visible improvements in skin firmness and radiance within 2–4 weeks[4] , GeneLift™ isn’t just a product—it’s a paradigm shift.

Backed by three core patents—including a novel synthesis method for acetyl hexapeptide-8 (a “synthetic snake venom” peptide)[5] —and formulated without alcohol, fragrance, or irritants, the system is safe even for sensitive and post-procedure skin. As dermatological innovation moves from clinics into bathrooms, Derminous stands at the forefront: proving that true transformation begins not with disruption, but with intelligent, closed-loop care.

Footnotes
Footnotes
-
“Transdermal Drug Delivery via Microneedles”, National Institutes of Health (NIH), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934732/↩
-
“PDRN in Skin Regeneration: Mechanisms and Clinical Applications”, Journal of Cosmetic Dermatology, https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13456↩
-
“At-Home Aesthetic Devices Market to Reach $12.8B by 2027”, Grand View Research, https://www.grandviewresearch.com/industry-analysis/at-home-aesthetic-devices-market↩
-
Derminous Clinical User Feedback & In-House Efficacy Trials (2024), https://www.derminous.com/pages/clinical-evidence↩
-
Chinese Patent ZL202111504220.4 – “Method for Liquid-Phase Synthesis of Acetyl Hexapeptide-8 Analog”, State Intellectual Property Office of China, http://epub.cnipa.gov.cn/↩





